| Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer PW Kantoff, TJ Schuetz, BA Blumenstein, LM Glode, DL Bilhartz, ... Journal of Clinical Oncology 28 (7), 1099, 2010 | 926 | 2010 |
| Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a … MHA Hussain, GR MacVicar, DP Petrylak, RL Dunn, U Vaishampayan, ... Journal of Clinical Oncology 25 (16), 2218-2224, 2007 | 311 | 2007 |
| Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone LM Glode, J Robinson, SF Gould The Lancet 317 (8230), 1132-1134, 1981 | 289 | 1981 |
| Genetic ablation: targeted expression of a toxin gene causes microphthalmia in transgenic mice ML Breitman, S Clapoff, J Rossant, LC Tsui, LM Glode, IH Maxwell, ... Science 238 (4833), 1563-1565, 1987 | 263 | 1987 |
| A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients TW Flaig, DL Gustafson, LJ Su, JA Zirrolli, F Crighton, GS Harrison, ... Investigational new drugs 25 (2), 139-146, 2007 | 242 | 2007 |
| The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial A Ziada, A Barqawi, LM Glode, M Varella‐Garcia, F Crighton, S Majeski, ... The Prostate 60 (4), 332-337, 2004 | 173 | 2004 |
| Regulated expression of a diphtheria toxin A-chain gene transfected into human cells: possible strategy for inducing cancer cell suicide IH Maxwell, F Maxwell, LM Glode Cancer Research 46 (9), 4660-4664, 1986 | 172 | 1986 |
| Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma LM Glode, A Barqawi, F Crighton, ED Crawford, R Kerbel Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 166 | 2003 |
| Gonadotropin-releasing hormone and its receptor in normal and malignant cells GS Harrison, ME Wierman, TM Nett, LM Glode Endocrine-related cancer 11 (4), 725-748, 2004 | 165 | 2004 |
| A comprehensive characterization of the peptide and protein constituents of human seminal fluid KYC Fung, LM Glode, S Green, MW Duncan The prostate 61 (2), 171-181, 2004 | 158 | 2004 |
| Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI–CDK–cyclin cascade, and caspase 3 and PARP cleavages A Tyagi, C Agarwal, G Harrison, LM Glode, R Agarwal Carcinogenesis 25 (9), 1711-1720, 2004 | 155 | 2004 |
| Sequence of cDNA for rat cystathionine γ-lyase and comparison of deduced amino acid sequence with related Escherichia coli enzymes PF Erickson, IH Maxwell, LJ Su, M Baumann, LM Glode Biochemical Journal 269 (2), 335-340, 1990 | 145 | 1990 |
| Targeted ablation of pituitary gonadotropes in transgenic mice SK Kendall, TL Saunders, L Jin, RV Lloyd, LM Glode, TM Nett, RA Keri, ... Molecular endocrinology 5 (12), 2025-2036, 1991 | 125 | 1991 |
| Genetic control of B cell activation by bacterial lipopolysaccharide is mediated by multiple distinct genes or alleles LM Glode, DL Rosenstreich The Journal of Immunology 117 (6), 2061-2066, 1976 | 117 | 1976 |
| Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer TM Beer, GT Bernstein, JM Corman, LM Glode, SJ Hall, WL Poll, ... Clinical Cancer Research 17 (13), 4558-4567, 2011 | 113 | 2011 |
| Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study TB Dorff, TW Flaig, CM Tangen, MHA Hussain, GP Swanson, DP Wood Jr, ... Journal of Clinical Oncology 29 (15), 2040, 2011 | 112 | 2011 |
| Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer R Sharifi, M Soloway The Journal of urology 143 (1), 68-71, 1990 | 112 | 1990 |
| Resistance of macrophages from C3H/HeJ mice to the in vitro cytotoxic effects of endotoxin LM Glode, A Jacques, SE Mergenhagen, DL Rosenstreich The Journal of Immunology 119 (1), 162-166, 1977 | 109 | 1977 |
| Lipid catabolism via CPT1 as a therapeutic target for prostate cancer IR Schlaepfer, L Rider, LU Rodrigues, MA Gijón, CT Pac, L Romero, ... Molecular cancer therapeutics 13 (10), 2361-2371, 2014 | 107 | 2014 |
| Lack of responsiveness of C3H/HeJ macrophages to lipopolysaccharide: the cellular basis of LPS-stimulated metabolism JL Ryan, LM Glode, DL Rosenstreich The Journal of Immunology 122 (3), 932-935, 1979 | 103 | 1979 |
